[Application of immunosuppressants in patients with autosomal dominant polycystic kidney disease after kidney transplantation].

OBJECTIVE To investigate the optimal dose range of immunosuppressants in patients with autosomal dominant polycystic kidney disease (ADPKD) after renal transplantation. METHODS A cohort of 68 patients with ADPKD who received their first renal transplantation between March, 2000 and January, 2018 in our institute were retrospectively analyzed, with 68 non-ADPKD renal transplant recipients matched for gender, age and date of transplant as the control group. We analyzed the differences in patient and renal survival rates, postoperative complications and concentrations of immunosuppressive agents between the two groups at different time points within 1 year after kidney transplantation. The concentrations of the immunosuppressants were also compared between the ADPKD patients with urinary tract infections (UTI) and those without UTI after the transplantation. RESULTS The recipients with ADPKD and the control recipients showed no significantly difference in the overall 1-, 5-, and 10- year patient survival rates (96.6% vs 96.0%, 94.1% vs 93.9%, and 90.6% vs 93.9%, respectively; P > 0.05), 1-, 5-, and 10-year graft survival rates (95.2% vs 96.0%, 90.8% vs 87.2%, and 79.0% vs 82.3%, respectively; P > 0.05), or the incidences of other post- transplant complications including acute rejection, gastrointestinal symptoms, cardiovascular events, pneumonia, and neoplasms (P > 0.05). The plasma concentrations of both tacrolimus and mycophenolate mofetil (MPA) in ADPKD group were significantly lower than those in the control group at 9 months after operation (P < 0.05). The incidence of UTI was significantly higher in ADPKD patients than in the control group (P < 0.05). In patients with ADPKD, those with UTI after transplantation had a significantly higher MPA plasma concentration (P < 0.05). CONCLUSIONS In patients with ADPKD after renal transplant, a higher dose of MPA is associated with a increased risk of UTI, and their plasma concentrations of immunosuppressants for long-term maintenance of immunosuppression regimen can be lower than those in other kidney transplantation recipients.

[1]  L. Harrington,et al.  Urinary T cells correlate with rate of renal function loss in autosomal dominant polycystic kidney disease , 2019, Physiological reports.

[2]  Jie Zhou,et al.  Interactions between Macrophages and Cyst-Lining Epithelial Cells Promote Kidney Cyst Growth in Pkd1-Deficient Mice. , 2018, Journal of the American Society of Nephrology : JASN.

[3]  M. K. Ma,et al.  mTOR Inhibition and Kidney Diseases , 2018, Transplantation.

[4]  Wenzheng Zhang,et al.  Insights into cellular and molecular basis for urinary tract infection in autosomal-dominant polycystic kidney disease. , 2017, American journal of physiology. Renal physiology.

[5]  R. Gansevoort,et al.  Tolvaptan and Kidney Pain in Patients With Autosomal Dominant Polycystic Kidney Disease: Secondary Analysis From a Randomized Controlled Trial , 2016, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[6]  Z. Tandoğdu,et al.  Urinary Tract Infections in Immunocompromised Patients with Diabetes, Chronic Kidney Disease, and Kidney Transplant. , 2016, European urology focus.

[7]  L. Zsom,et al.  Bacterial Infections After Kidney Transplantation: A Single-Center Experience. , 2016, Transplantation proceedings.

[8]  D. Wallace,et al.  Autocrine IL-10 activation of the STAT3 pathway is required for pathological macrophage differentiation in polycystic kidney disease , 2016, Disease Models & Mechanisms.

[9]  F. Thaiss,et al.  Immunological risk assessment: The key to individualized immunosuppression after kidney transplantation. , 2016, Transplantation reviews.

[10]  Y. Ubara,et al.  Cyst infection in autosomal dominant polycystic kidney disease: causative microorganisms and susceptibility to lipid-soluble antibiotics , 2015, European Journal of Clinical Microbiology & Infectious Diseases.

[11]  O. Devuyst,et al.  Renal transplantation in autosomal dominant polycystic kidney disease , 2014, Nature Reviews Nephrology.

[12]  P. Friend,et al.  Pretransplant identification of acute rejection risk following kidney transplantation , 2014, Transplant international : official journal of the European Society for Organ Transplantation.

[13]  R. Miano,et al.  Laparoscopic pretransplant nephrectomy with morcellation in autosomic-dominant polycystic kidney disease patients with end-stage renal disease , 2014, Surgical Endoscopy.

[14]  Carsten Bergmann,et al.  ARPKD and early manifestations of ADPKD: the original polycystic kidney disease and phenocopies , 2014, Pediatric Nephrology.

[15]  Y. Lotan,et al.  Impact of fluid intake in the prevention of urinary system diseases: a brief review , 2013, Current opinion in nephrology and hypertension.

[16]  L. Rostaing,et al.  Outcomes of renal transplantation in patients with autosomal dominant polycystic kidney disease: a nationwide longitudinal study , 2011, Transplant international : official journal of the European Society for Organ Transplantation.

[17]  J. Bradley,et al.  Immunosuppressive agents in solid organ transplantation: Mechanisms of action and therapeutic efficacy. , 2005, Critical reviews in oncology/hematology.